rabbit polyclonal antibodies against ps6  (Cell Signaling Technology Inc)

Journal: BMC Gastroenterology

Article Title: Glucose metabolic upregulation via phosphorylation of S6 ribosomal protein affects tumor progression in distal cholangiocarcinoma

doi: 10.1186/s12876-023-02815-2

Figure Lengend Snippet: Representative images of immunohistochemistry for scoring of staining intensity for pS6 and GLUT1 in distal cholangiocarcinoma tissues

Article Snippet: We performed Immunohistochemistry with rabbit polyclonal antibodies against pS6 (S240/244) diluted 1:400 (Cell Signaling Technology, Danvers, MA, USA) and GLUT1 diluted 1:100 (Abcam, Tokyo, Japan).

Techniques: Immunohistochemistry, Staining

Journal: BMC Gastroenterology

Article Title: Glucose metabolic upregulation via phosphorylation of S6 ribosomal protein affects tumor progression in distal cholangiocarcinoma

doi: 10.1186/s12876-023-02815-2

Figure Lengend Snippet: Patient characteristics

Article Snippet: We performed Immunohistochemistry with rabbit polyclonal antibodies against pS6 (S240/244) diluted 1:400 (Cell Signaling Technology, Danvers, MA, USA) and GLUT1 diluted 1:100 (Abcam, Tokyo, Japan).

Techniques:

Journal: BMC Gastroenterology

Article Title: Glucose metabolic upregulation via phosphorylation of S6 ribosomal protein affects tumor progression in distal cholangiocarcinoma

doi: 10.1186/s12876-023-02815-2

Figure Lengend Snippet: Relationship between S6 phosphorylation or GLUT1 and patient characteristics

Article Snippet: We performed Immunohistochemistry with rabbit polyclonal antibodies against pS6 (S240/244) diluted 1:400 (Cell Signaling Technology, Danvers, MA, USA) and GLUT1 diluted 1:100 (Abcam, Tokyo, Japan).

Techniques: Phospho-proteomics

Journal: BMC Gastroenterology

Article Title: Glucose metabolic upregulation via phosphorylation of S6 ribosomal protein affects tumor progression in distal cholangiocarcinoma

doi: 10.1186/s12876-023-02815-2

Figure Lengend Snippet: a - c Scatter plots showing the relationship between GLUT1 and pS6, GLUT1 and SUV-max of FDG-PET, and pS6 and SUV-max of FDG-PET. d Representative images of immunohistochemistry using antibodies against GLUT1 and pS6 in distal cholangiocarcinoma tissues

Article Snippet: We performed Immunohistochemistry with rabbit polyclonal antibodies against pS6 (S240/244) diluted 1:400 (Cell Signaling Technology, Danvers, MA, USA) and GLUT1 diluted 1:100 (Abcam, Tokyo, Japan).

Techniques: Immunohistochemistry

Journal: Journal of cancer science and clinical therapeutics

Article Title: Systemic Delivery of a Dual PI3K/mTOR Inhibitor More Effective than Topical Delivery in Preventing Anal Carcinogenesis in an HPV Transgenic Mouse Model

doi: 10.26502/jcsct.5079153

Figure Lengend Snippet: Mean pAKT and pS6 protein expression, markers of PI3K and mTOR activity respectively, quantified via immunohistochemical staining sections of K14E6/E7 mice anal tissue. Mean ± standard deviation values are reported in the RawIntDen/Area (raw integrated density/area). The notation * represents statistical significance (p < 0.05). A, B. Mice that began treatment at 5 weeks of age/ normal anal histology. C, D. Mice that began treatment at 15 weeks of age/ low-grade anal dysplasia. E, F. Mice that began treatment at 25 weeks of age/ high-grade anal dysplasia.

Article Snippet: Sections were then stained with a monoclonal rabbit antibody against pAKT serine 473 (1:50 in 5% horse serum in PBS, antibody #3787; Cell Signaling Technology, Danvers, Massachusetts, USA) or a polyclonal rabbit antibody against pS6 ribosomal protein Ser235/236 (1:50 in 5% horse serum in PBS, antibody #2211; Cell Signaling Technology, Danvers, MA, USA) overnight at 4°C.

Techniques: Expressing, Activity Assay, Immunohistochemical staining, Staining, Standard Deviation

Journal: Experimental and molecular pathology

Article Title: PI3K/mTOR inhibition prevents anal cancer in mice with established low-grade anal dysplasia.

doi: 10.1016/j.yexmp.2022.104752

Figure Lengend Snippet: Fig. 1. K14E6/E7 mice anal tissue after 2-week treatment with varying concentrations of LY3023414, to determine lowest dosage that results in PI3K and mTOR inhibition. The sections of tissue are immunohistochemically stained for pAKT (A-E) or pS6 (F-J). Tissue was reviewed under light microscope and 200× magni fication images were acquired using the Zeiss Axio Imager M2 imaging system. These images demonstrate that 1% LY3023414 was the lowest concentration that provided the greatest inhibition of PI3K and mTOR based on decreased levels of pAKT and pS6.

Article Snippet: Sections were then stained with a monoclonal rabbit antibody against pAKT (1:50 in 5% horse serum in phosphate buffered saline (PBS); antibody #3787, Cell Signaling Technology) or a polyclonal rabbit antibody against pS6 (1:50 in 5% horse serum in PBS; antibody #2211, Cell Signaling Technology) overnight at 4◦ Celsius.

Techniques: Inhibition, Staining, Light Microscopy, Imaging, Concentration Assay

Journal: Experimental and molecular pathology

Article Title: PI3K/mTOR inhibition prevents anal cancer in mice with established low-grade anal dysplasia.

doi: 10.1016/j.yexmp.2022.104752

Figure Lengend Snippet: Fig. 3. Treatment with systemic LY3023414 effectively decreased PI3K and mTOR Activity. 3A Effect of systemic LY3023414 on pAKT protein expression quantified via immunohistochemical staining of the mouse anorectal transition zone. Mean ± standard deviation values are reported in the RawIntDen/Area (raw integrated density/area) of intensity signal. The notation * represents statistical significance (p < 0.05). 3B Effect of systemic LY3023414 on pS6 protein expression quantified via immunohistochemical staining of the mouse anorectal transition zone. Mean ± standard deviation values are reported in RawIntDen/Area (raw integrated density/area) of intensity signal.The notation * represents statistical significance (p < 0.05). 3C Sections of K14E6/E7 mice anal tissue after the 20-week treatment period, immunohistochemically stained for pAKT (A-D) or pS6 (E-H). A,E. no treatment, B,F. topical DMBA alone, C,G. systemic LY3023414 alone and D,H. systemic LY3023414 and topical DMBA.

Article Snippet: Sections were then stained with a monoclonal rabbit antibody against pAKT (1:50 in 5% horse serum in phosphate buffered saline (PBS); antibody #3787, Cell Signaling Technology) or a polyclonal rabbit antibody against pS6 (1:50 in 5% horse serum in PBS; antibody #2211, Cell Signaling Technology) overnight at 4◦ Celsius.

Techniques: Activity Assay, Expressing, Immunohistochemical staining, Staining, Standard Deviation